Alm. Brand A/S
Alm. Brand A/S – Weekly report on share buybacks
Alm. Brand A/S – Weekly report on share buybacks
Alm. Brand A/S share buy-back program
Transactions during 25 August 2025 – 29 August 2025
On 5 March 2025, Alm. Brand A/S announced a share buy-back program of up to DKK 835.2 million, as described in company announcement no. 21/2025.
The program is carried out in accordance with the Regulation No 596/2014 of the European Parliament and Council of 16 April 2014 (MAR) and the Commission Delegated Regulation (EU) 2016/1052, also referred to as the Safe Harbour Regulations.
The following transactions were made under the share buy-back program during week number 35
| Number of shares bought | Average purchase price | Amount (DKK) | |
| Accumulated, last announcement | 23,675,000 | 16.36 | 387,330,750 |
| 25 August 2025 | 150,000 | 18.54 | 2,781,000 |
| 26 August 2025 | 150,000 | 18.59 | 2,788,500 |
| 27 August 2025 | 150,000 | 18.28 | 2,742,000 |
| 28 August 2025 | 170,000 | 17.91 | 3,044,700 |
| 29 August 2025 | 170,000 | 17.89 | 3,041,300 |
| Total, week number 35 | 790,000 | 18.22 | 14,397,500 |
| Accumulated under the program | 24,465,000 | 16.42 | 401,728,250 |
With the transactions stated above Alm. Brand A/S holds a total of 28,710,696 own shares corresponding to 1.98 % of the total number of outstanding shares.
Contact
Please direct any questions regarding this announcement to:
Investors and equity analysts:
Head of Investor Relations & ESG
Mads Thinggaard
Mobile no. +45 2025 5469
Attachments
Documents
Subscribe to releases from Globenewswire
Subscribe to all the latest releases from Globenewswire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Globenewswire
Rapafusyn Pharmaceuticals4.9.2025 20:24:11 CEST | Press release
Rapafusyn Pharmaceuticals Closes Over-Subscribed $44 Million Series A Financing to Advance Its Non-Degrading Molecular Glue Drug Discovery Platform
Avania4.9.2025 19:35:16 CEST | Press release
Avania Strengthens Leadership Team with Appointment of Four New Executives
Vaisala Group4.9.2025 17:30:00 CEST | Press release
Vaisala Corporation: Share Repurchase 4.9.2025
LambdaTest, Inc.4.9.2025 17:00:00 CEST | Press release
Boomi Achieves 78% Faster Testing Cycles Using LambdaTest’s HyperExecute Platform
AIM ImmunoTech Inc.4.9.2025 17:00:00 CEST | Press release
AIM ImmunoTech Highlights Growing Body of Compelling Data of Ampligen for the Treatment of Pancreatic Cancer at Conference in Poland
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom